Have a feature idea you'd love to see implemented?
Let us know!
ACRV Acrivon Therapeutics Inc
Price (delayed)
$8.195
Market cap
$253.82M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.78
Enterprise value
$211.61M
We are a clinical stage biopharmaceutical company developing precision oncology medicines that we match to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing our
Highlights
ACRV's equity has soared by 100% QoQ and by 45% YoY
Acrivon Therapeutics's debt has decreased by 8% YoY and by 5% QoQ
The EPS has plunged by 100% YoY but it has grown by 3.8% from the previous quarter
ACRV's quick ratio is up by 31% from the previous quarter but it is down by 26% YoY
ACRV's net income has dropped by 54% year-on-year and by 8% since the previous quarter
Key stats
What are the main financial stats of ACRV
Market
Valuations
Earnings
Shares outstanding
30.97M
Market cap
$253.82M
Enterprise value
$211.61M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.17
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$69M
EBITDA
-$67.42M
Free cash flow
-$55.26M
Per share
Balance sheet
Liquidity
EPS
-$2.78
Free cash flow per share
-$1.53
Book value per share
$7
Revenue per share
$0
TBVPS
$6.38
Total assets
$230.59M
Total liabilities
$14.53M
Debt
$4.22M
Equity
$216.06M
Working capital
$171.07M
Debt to equity
0.02
Current ratio
16.16
Quick ratio
16.04
Net debt/EBITDA
0.63
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-43.1%
Return on equity
-47.3%
Return on invested capital
-57.8%
Return on capital employed
-31.5%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ACRV stock price
How has the Acrivon Therapeutics stock price performed over time
Intraday
1.8%
1 week
7.83%
1 month
9.71%
1 year
47.92%
YTD
66.57%
QTD
17.07%
Financial performance
How have Acrivon Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$76.3M
Net income
-$69M
Gross margin
N/A
Net margin
N/A
ACRV's net income has dropped by 54% year-on-year and by 8% since the previous quarter
The operating income has dropped by 54% year-on-year and by 8% since the previous quarter
Growth
What is Acrivon Therapeutics's growth rate over time
Valuation
What is Acrivon Therapeutics stock price valuation
P/E
N/A
P/B
1.17
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has plunged by 100% YoY but it has grown by 3.8% from the previous quarter
ACRV's equity has soared by 100% QoQ and by 45% YoY
The P/B is 4.2% below the last 4 quarters average of 1.2
Efficiency
How efficient is Acrivon Therapeutics business performance
The ROIC has contracted by 50% YoY but it has grown by 6% from the previous quarter
The ROA has contracted by 44% YoY but it has grown by 4.2% from the previous quarter
Acrivon Therapeutics's return on equity has decreased by 15% YoY but it has increased by 4.8% QoQ
Dividends
What is ACRV's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ACRV.
Financial health
How did Acrivon Therapeutics financials performed over time
The total assets has soared by 91% since the previous quarter and by 44% year-on-year
ACRV's total liabilities is up by 34% year-on-year and by 16% since the previous quarter
Acrivon Therapeutics's debt is 98% lower than its equity
ACRV's equity has soared by 100% QoQ and by 45% YoY
The debt to equity has dropped by 50% since the previous quarter and by 33% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.